In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach
- PMID: 17102958
- DOI: 10.1007/s00240-006-0073-1
In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach
Abstract
Cyclic nucleotide phosphodiesterase (PDE) isoenzymes are key proteins regulating intracellular cyclic nucleotide turnover and thus smooth muscle tension. Several in vitro studies have indicated that the cyclic GMP and cyclic AMP-mediated signaling may play a role in the control of human ureteral muscle. The aim of the present study was to evaluate the functional effects of PDE5 inhibitors sildenafil (Sil), vardenafil (Var) and tadalafil (Tad), as well as nitric oxide (NO)-donating agent sodium nitroprusside (SNP) and non-selective muscarinic antagonist butylscopolamine (BSC) on the tension induced by KCl and the turnover of cyclic nucleotides in isolated human ureteral smooth muscle. In vitro relaxant responses of human ureteral smooth muscle to the PDE5 inhibitors mentioned above were investigated using the organ bath technique. Cyclic nucleotides cAMP and cGMP were determined by means of specific radioimmunoassay following incubation of the tissue with Sil, Var, Tad and SNP. The tension induced by KCl of the ureteral tissue was dose dependently reversed by the drugs with the following rank order of efficacy: SNP > Var >or= Sil > Tad > BSC. R(max) values ranged from 25 +/- 9% (SNP) to 5 +/- 3% (BSC). Relaxant responses were paralleled by threefold to fourfold increase in tissue levels of cGMP. Our results indicate that PDE5 inhibitors can reverse the tension of isolated human ureteral smooth muscle via cGMP-mediated pathways. Nevertheless, further studies are indicated in order to evaluate as to whether there might be a use for PDE5 inhibitors in the treatment of ureteral stone disease.
Similar articles
-
[PDE5 inhibitors. A new option in the treatment of ureteral colic?].Urologe A. 2007 Sep;46(9):1219-23. doi: 10.1007/s00120-007-1409-3. Urologe A. 2007. PMID: 17604974 German.
-
The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.Int J Impot Res. 2001 Oct;13(5):282-90. doi: 10.1038/sj.ijir.3900726. Int J Impot Res. 2001. PMID: 11890515
-
Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.Clin Exp Pharmacol Physiol. 2009 Apr;36(4):358-66. doi: 10.1111/j.1440-1681.2008.05071.x. Epub 2008 Oct 15. Clin Exp Pharmacol Physiol. 2009. PMID: 18986324 Free PMC article.
-
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.Am J Cardiol. 2003 Nov 6;92(9A):9M-18M. doi: 10.1016/s0002-9149(03)00824-5. Am J Cardiol. 2003. PMID: 14609619 Review.
-
Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.Curr Pharm Des. 2005;11(31):4047-58. doi: 10.2174/138161205774913426. Curr Pharm Des. 2005. PMID: 16378510 Review.
Cited by
-
Drugs to affect the smooth musculature of the human ureter - an update with integrated information from basic science to the use in medical expulsion therapy (MET).World J Urol. 2024 Nov 28;42(1):654. doi: 10.1007/s00345-024-05368-5. World J Urol. 2024. PMID: 39609287 Free PMC article. Review.
-
The effect of phosphodiesterase-5 inhibitor, tadalafil, on in vitro potassium chloride-induced contractions of isolated human ureteral tissue.Indian J Urol. 2018 Oct-Dec;34(4):287-291. doi: 10.4103/iju.IJU_107_18. Indian J Urol. 2018. PMID: 30337785 Free PMC article.
-
cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Pharmacol Rev. 2010 Sep;62(3):525-63. doi: 10.1124/pr.110.002907. Pharmacol Rev. 2010. PMID: 20716671 Free PMC article. Review.
-
Inhibition of PDE-4 isoenzyme attenuates frequency and overall contractility of agonist-evoked ureteral phasic contractions.Pharmacol Res Perspect. 2024 Feb;12(1):e1175. doi: 10.1002/prp2.1175. Pharmacol Res Perspect. 2024. PMID: 38339883 Free PMC article.
-
A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms.World J Urol. 2018 Nov;36(11):1877-1881. doi: 10.1007/s00345-018-2339-y. Epub 2018 May 15. World J Urol. 2018. PMID: 29766318 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical